Kobayashi Pharmaceutical Co (4967) AI Stock Analysis

• Market Cap: ¥427.62B
• Dividend Yield: 1.95%
• Average Volume (3M): 221.72K
• Price to Earnings (P/E): 110.4
• Beta (1Y): 0.33
• Revenue Growth: -3.33%
• EPS Growth: 13.76%
• Country: JP
• Employees: 3,615
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -42.41
• Shares Outstanding: 78,050,000
• 10 Day Avg. Volume: 218,190
• 30 Day Avg. Volume: 221,720
• PEG Ratio: -1.73
• Price to Book (P/B): 1.91
• Price to Sales (P/S): 2.43
• P/FCF Ratio: 32.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,281.00
• Price Target Upside: -1.62% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1
• EPS Forecast (FY): 164.83
• Revenue Forecast (FY): ¥173.45B

• Rating: 65 Neutral
• Price Target: ¥5,952.00 ▲(10.88% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily supported by a very strong, low-debt balance sheet and improving 2025 cash generation, alongside moderately positive price momentum. Offsetting these positives are the sharp deterioration in profitability since 2023 and a very high P/E valuation.

Positive Factors

Conservative balance sheet

Minimal debt and large stable equity provide durable financial resilience. Low leverage reduces solvency risk, preserves borrowing capacity for capex or M&A, and supports ongoing operations and payouts during cyclical weakness, strengthening strategic optionality over months.

Negative Factors

Sharp profitability deterioration

A steep multi-year decline in net income signals material margin pressure and weakening operating performance. Persistently lower profits constrain reinvestment, limit flexibility on pricing or promotions, and erode long-term returns unless structural cost or revenue drivers are restored.

Kobayashi Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offe...

Read more

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offe...

How the Company Makes Money

Kobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health...

Read more

Kobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health...

Kobayashi Pharmaceutical Co Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	161.48B	165.74B	165.60B	173.46B	166.26B	155.25B
Gross Profit	82.99B	84.71B	87.60B	96.38B	92.33B	88.77B
EBITDA	23.61B	12.52B	21.96B	33.65B	33.33B	32.49B
Net Income	11.80B	3.66B	10.07B	20.34B	20.02B	19.71B
Balance Sheet
Total Assets	260.71B	275.33B	265.37B	267.47B	255.83B	252.55B
Cash, Cash Equivalents and Short-Term Investments	69.67B	70.61B	65.75B	79.84B	104.53B	109.05B
Total Debt	749.00M	678.00M	846.00M	987.00M	792.00M	630.00M
Total Liabilities	52.47B	64.32B	51.89B	62.66B	57.93B	56.95B
Stockholders Equity	208.24B	211.00B	213.47B	204.82B	197.90B	195.60B
Cash Flow
Free Cash Flow	0.00	12.34B	-14.81B	5.60B	17.17B	18.76B
Operating Cash Flow	0.00	25.59B	11.25B	18.36B	31.91B	22.42B
Investing Cash Flow	0.00	-154.00M	-18.41B	-19.58B	-14.31B	7.99B
Financing Cash Flow	0.00	-7.92B	-7.77B	-19.46B	-20.76B	-10.38B

Kobayashi Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5368.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Positive. The current price of 5368 is below the 20-day moving average (MA) of 5662.95, below the 50-day MA of 5553.90, and above the 200-day MA of 5356.72, indicating a bullish trend. The MACD of 21.00 indicates Positive momentum. The RSI at 55.40 is Neutral, neither overbought nor oversold. The STOCH value of 50.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4967.

Kobayashi Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4912	76 Outperform	¥437.50B	16.53	9.09%	1.73%	2.18%	60.81%
4527	71 Outperform	¥552.66B	13.97	12.66%	1.53%	18.35%	31.87%
4452	70 Outperform	¥2.74T	24.05	11.50%	2.41%	4.62%	47.68%
4922	69 Neutral	¥333.57B	19.79	2.72%	2.61%	1.37%	-5.60%
4967	65 Neutral	¥427.62B	110.37	5.37%	1.95%	-3.33%	13.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4911	56 Neutral	¥1.22T	68.83	―	2.11%	-1.20%	-2896.72%